Hong-Yu Li

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8655491/publications.pdf

Version: 2024-02-01

1040056 940533 13 294 9 16 citations h-index g-index papers 17 17 17 413 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Irbesartan ameliorates hyperlipidemia and liver steatosis in type 2 diabetic db/db mice via stimulating PPAR-Î ³ , AMPK/Akt/mTOR signaling and autophagy. International Immunopharmacology, 2017, 42, 176-184.	3.8	56
2	Metadherin facilitates podocyte apoptosis in diabetic nephropathy. Cell Death and Disease, 2016, 7, e2477-e2477.	6.3	54
3	Micheliolide alleviates hepatic steatosis in db/db mice by inhibiting inflammation and promoting autophagy via PPAR-γ-mediated NF-аB and AMPK/mTOR signaling. International Immunopharmacology, 2018, 59, 197-208.	3.8	50
4	Micheliolide ameliorates renal fibrosis by suppressing the Mtdh/BMP/MAPK pathway. Laboratory Investigation, 2019, 99, 1092-1106.	3.7	25
5	Dimethylaminomicheliolide ameliorates peritoneal fibrosis through the activation of autophagy. Journal of Molecular Medicine, 2019, 97, 659-674.	3.9	21
6	The PAR-1 antagonist vorapaxar ameliorates kidney injury and tubulointerstitial fibrosis. Clinical Science, 2020, 134, 2873-2891.	4.3	20
7	Cyclopropanyldehydrocostunolide LJ attenuates high glucose-induced podocyte injury by suppressing RANKL/RANK-mediated NF-κB and MAPK signaling pathways. Journal of Diabetes and Its Complications, 2016, 30, 760-769.	2.3	14
8	Aprikalim reduces the Na + -Ca 2+ exchange outward current enhanced by hyperkalemia in rat ventricular myocytes. Annals of Thoracic Surgery, 2002, 73, 1253-1259.	1.3	10
9	Irbesartan Ameliorates Diabetic Nephropathy by Suppressing the RANKL-RANK-NF- <i>κ</i> B Pathway in Type 2 Diabetic db/db Mice. Mediators of Inflammation, 2016, 2016, 1-10.	3.0	10
10	Pseudolaric acid B ameliorates synovial inflammation and vessel formation by stabilizing PPARγ to inhibit NFâ€₽B signalling pathway. Journal of Cellular and Molecular Medicine, 2021, 25, 6664-6678.	3.6	10
11	Patients' and clinicians' expectations on integrative medicine Services for Diabetes: a focus group study. BMC Complementary Medicine and Therapies, 2020, 20, 205.	2.7	9
12	Potential Therapeutic Targets of Rehmannia Formulations on Diabetic Nephropathy: A Comparative Network Pharmacology Analysis. Frontiers in Pharmacology, 2022, 13, 794139.	3.5	8
13	Tubule-specific deletion of LincRNA-p21 ameliorates lipotoxic kidney injury. Molecular Therapy - Nucleic Acids, 2021, 26, 1280-1290.	5.1	3